KROS
Keros TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
Positive mid-stage clinical data and a partnership would materially de-risk the franchise, supporting >30% upside to the anchor within a few quarters.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
Clinical failure, regulatory delay, or short cash runway could compress valuation toward the low-teens or below, driven by binary outcomes and near-term dilution.
Momentum
16
Value
44
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $19.22 · Bull $23.58 · Bear $13.10
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-13 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $21.83
Why
Momentum16 · Δ7d +10.9
Value44 · Δ7d 0.0
Sentiment100 · Δ7d 0.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
16
26% active weight
Current posture
7d trendSoftening
Δ7d
+10.9
Δ21d
+9.6
Value
44
39% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.1
Sentiment
100
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade B. Momentum 16.2 / Value 44.2 / Sentiment 100.0
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$209.2M
Beta
0.87
Shares Out
19.79M
P/E (TTM)
11.6
P/S (TTM)
2.21
P/FCF (TTM)
6.27
Rev YoY
-99.8%
EPS YoY
-133.4%
Gross Margin
+95.3%
Op Margin
+17.7%
Net Debt
-$270.53M
Current Ratio
22.62
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology